Feasibility of Early Palliative Care Consultation for Children With High-Risk Malignancies

Laila A Mahmood1, Denise Casey2, James G Dolan3

  • 1Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Rochester Medical Center, Rochester, New York.

Insights

Early palliative care is feasible for children with high-risk cancer. Consultations were accepted by families and staff, improving support during treatment and enhancing communication for better outcomes.

Area of Science:

  • Pediatric Oncology
  • Palliative Care Medicine

Background:

  • Children with cancer experience significant morbidity and uncertain prognoses.
  • Palliative care teams offer crucial support for symptom management and communication.
  • Early palliative care consultation aims to enhance support for pediatric cancer patients.

Purpose of the Study:

  • To assess the feasibility of early palliative care consultation for children with high-risk malignancies.
  • To evaluate the acceptability of palliative care services among patients, families, and healthcare professionals.
  • To determine the impact of early consultation on patient outcomes and survival.

Main Methods:

  • A prospective study involving children under 22 with high-risk malignancies, recurrence, or requiring hematopoietic stem cell transplantation (HSCT).
  • Data collection included diagnosis, time to consultation, and patient/family satisfaction.
  • Feasibility defined by >75% enrollment, consultation within 1 month, and high satisfaction rates.

Main Results:

  • 80% of eligible patients received early palliative care consultation.
  • 85% of consultations occurred within 30 days of eligibility.
  • No families or oncologists declined the consultation, indicating high acceptability.

Conclusions:

  • Early palliative care consultation is a feasible and acceptable intervention for children with high-risk cancer.
  • The integration of palliative care enhances support systems for pediatric oncology patients.
  • This approach benefits children, families, and pediatric oncology teams.
Abstract